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Toxicity of parenteral iron dextran therapy. Parenteral iron PARENTERAL IRON SIDE-EFFECTS
dextran is efficacious and safe for iron repletion in patients
Approximately 26% of all patients receiving paren-with iron-deficiency anemia. The risk for developing reactions
teral iron therapy experience side-effects, but the major-to parenteral iron infusion can be attenuated if patients are
carefully selected. Patients with underlying autoimmune dis- ity are self-limited and mild. Three percent of patients
ease, malnutrition with indolent infection, and risk for iron have more severe symptoms, with 0.1% to 0.6% devel-
overload syndromes should be carefully monitored for compli- oping life-threatening anaphylaxis [4]. Most reactions tocations. Further, the rate of infusion and the route of adminis-
parenteral iron therapy occur immediately during admin-tration of iron dextran play roles in the risk of adverse reactions.
istration of the test dose and may include dyspnea, head-The purpose of this review is to identify and elucidate the
mechanisms of the acute and chronic toxicities associated with ache, flushing, chest pain, abdominal or back pain, nau-
parenteral iron dextran use. sea, emesis, bronchospasm, fever, seizures, hypotension,
urticaria, and anaphylaxis. Delayed reactions occurring
one to three days after infusion are related to deposition
Iron deficiency is the most common cause of anemia of iron in tissues and include myalgia, arthralgia, phlebi-
worldwide. The causes of iron deficiency include inade- tis, and lymphadenopathy.
quate intake, chronic body loss, or a combination of In a review of 2400 patients who received parenteral
both. Usually, repletion of iron stores can be simply iron dextran therapy, Wallerstein reported that only 1%
achieved with increased oral iron intake in the form of to 2% of patients experienced significant side-effects [5].
supplements. However, some patients are intolerant to Most of reactions were mild and transient and were simi-
oral iron therapy or have gastrointestinal dysfunction lar regardless of the route of administration (intramuscu-
that prohibits achieving adequate intake through dietary lar vs. intravenous). No fatalities were reported in this
means. Under these circumstances, parenteral iron reple- series.
tion provides a means to replete total body iron stores. Hamstra et al studied 481 patients given intravenous
Generally, parenteral iron therapy is safe and efficacious, iron dextran at doses ranging from 250 to 500 mg infused
but injudicious use can be toxic and can lead to significant at a rate of approximately 100 mg per minute. Overall,
morbidity and/or mortality (Table 1). 125 patients (26%) experienced side-effects, most of
Parenteral iron dextran has been used to replete iron which were mild and self-limiting. Eight were delayed
stores in patients on chronic hemodialysis, with chronic reactions characterized by arthralgia, myalgia, fever, ad-
gastrointestinal losses, and in surgical patients refusing
enopathy, thrombophlebitis, pulmonary embolism, or er-
blood transfusion. Adverse reactions included range
ythema nodosum. Three of 481 patients developed life-from mild acute allergic to severe anaphylactic reactions,
threatening anaphylactoid reactions characterized by hy-exacerbation of autoimmune disease, muscle disease,
potension, cyanosis, syncope, bronchospasm, purpura,connective tissue malignancy, iron overload syndromes,
and respiratory arrest. Severe reactions were associatedand infection with impaired immunity. Multiple authors
with infusion of larger iron doses (more than 500 mg).have documented the safety of parenteral iron therapy
Side-effects were more prevalent in small women, espe-both in the nonuremic and hemodialysis-dependent pa-
cially those with pre-existing collagen vascular disease [4].tient population [1–5]. However, the toxicity profile and
Auerbach et al studied iron dextran infusion in 87mechanisms of these reactions need to be clarified so
patients with iron-deficiency anemia to determine thethat risks associated with parenteral iron can be reduced.
side-effect profile, optimal rate of infusion, the role of
premedication consisting of diphenhydramine, methyl-
prednisolone, and subcutaneous epinephrine to avoidKey words: anemia, malnutrition, iron deficiency, hemodialysis, blood
transfusion. symptoms [6]. Two patients had anaphylactoid reactions
in response to the test dose. Symptoms were relieved 1999 by the International Society of Nephrology
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Table 1. Side-effects and complications of parenteral iron dextran fered from systemic lupus erythematosis, suggesting that
patients with autoimmune disease may be more sensitiveShort-term
Anaphylaxis Urticaria to iron dextran therapy.
Hypotension Nausea or emesis There are several reports of the safe administrationBronchospasm Pruritis
of iron dextran to patients with prior episodes of allergicFever Seizures
Arthalgia Headache type reactions. Monaghan et al provide a case report of
Myalgia Flushing an 83-year-old man with iron-deficiency anemia second-Lymphadenopathy Phlebitis
ary to chronic gastrointestinal blood loss from an un-Chest, back or abdominal pain Rigors
Infection known etiology. The patient underwent multiple endo-
Long-term complications (both i.m. and i.v.) scopic evaluations, but the source of the bleeding couldIron overload syndrome
not be located. After several blood transfusions, oralComplications of intramuscular administration
Chronic pain at the site of injection iron-repletion therapy was attempted but was unsuccess-
Skin staining ful because of gastrointestinal intolerance. ParenteralLocal skin atrophy
total dose iron therapy was planned, and the patient wasAbscess
Sarcoma formation given a test dose of 25 mg of iron dextran over five
minutes. After one minute, the patient developed an
anaphylactoid response characterized by hypotension,
chest pain, and syncope, necessitating admission to the
intensive care unit. Despite this dramatic reaction to
with intravenous diphenhydramine, methylprednisolone, parenteral iron, a desensitization protocol was attempted
and subcutaneous epinephrine. Delayed transient reac- with iron dextran after the patient recovered. A pretreat-
tions of myalgia, arthralgia, and fever occurred in 37 ment protocol with methylprednisolone, diphenhydra-
patients and were controlled with nonsteroidal anti-in- mine, and ephedrine was administered prior to infusion
flammatory agents. The group recommended that the of 1 mg of iron dextran on day 1. Escalating doses of
total dose infusion of iron dextran was safe if patients parenteral iron dextran were safely administered over
received a test dose and if the infusion rate did not next several days after pretreatment until a total dose
exceed 6 mg per minute. of 2 g was achieved. The patient tolerated the iron infu-
Anemia in patients with end-stage renal disease on sions well without further allergic reaction [8].
hemodialysis is common, and parenteral iron supplemen- Porter, Blackburn and Bistrian reported on a 30-year-
tation is frequently employed in this patient population. old man with Crohn’s disease who was hospitalized for
Fishbane et al reviewed 573 patients on dialysis that were a flare with abdominal pain and diarrhea. Laboratories
treated with iron dextran. Twenty-seven (4.7%) had ad- demonstrated a mixed anemia of chronic disease and
verse reactions related to iron administration. Four iron deficiency. Bowel rest and total parenteral nutrition
(0.7%) patients had serious complications, one of which (TPN) via a central venous catheter were initiated. The
was a cardiac arrest, and three were hospitalized. Ten standard maintenance dose of 2 mg of iron dextran was
(1.7%) had anaphylactoid reactions and were treated provided daily in the TPN, and this was well tolerated.
with antihistamines, steroids, or epinephrine. In 22 Because of low serum iron levels, parenteral iron therapy
(3.8%) patients, reactions led to discontinuance of the was commenced after a test dose of 25 mg of iron dextran
iron dextran infusion. Of all reactions, five occurred to in 100 cc D5W was given over five minutes. Within min-
the test dose that was 50 mg or less of iron dextran, utes of the infusion, the patient experienced severe back-
although it is unclear whether all patients received test ache, extremity pain, and headache. The test dose was
doses [1]. discontinued, and diphenhydramine and meperidine
The mechanism(s) leading to iron dextran-induced were given, with resolution of symptoms. Subsequently,
symptoms remains unclear but is probably multifactorial. TPN containing 2 mg of iron dextran per day was admin-
Novey et al studied renal dialysis patients who developed istered and was well tolerated [9].
anaphylactoid reactions after parenteral iron therapy [7].
Tests performed included measurement of iron dextran-
IRON AND AUTOIMMUNE DISEASEinduced in vitro basophil degranulation and histamine
release, formation of type I anaphylaxis specific IgE anti- Total dose infusions of iron dextran have been re-
body, and immune complex activation by specific IgG ported to exacerbate symptoms of rheumatoid arthritis
antibody. Six patients undergoing hemodialysis who pre- and collagen vascular disease and have been associated
viously received iron dextran without reaction served as with a greater incidence of anaphylaxis in this popula-
controls. Of the study patients, only one demonstrated tion. In a study of 11 patients with rheumatoid arthritis
positive basophil histamine release test and formed spe- given total dose infusions of iron dextran, Blake et al
found that two patients had anaphylactic reactions andcific IgG to iron dextran. Interestingly, this patient suf-
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that nine had an exacerbation of synovitis. Quantitative ment of neoplasm. Greenberg reviewed 90 cases of sar-
coma of the buttock and noted that four patients hadinfrared thermal imaging demonstrated increased joint
inflammation in eight of the patients imaged. The exacer- received intramuscular iron compounds [15]. The first
patient was an 18-year-old man who developed a fibro-bation of synovitis occurred 24 to 48 hours after the
iron dextran infusion. This corresponded with increased sarcoma of the left buttock two years after receiving
injections of Jectofer, iron sorbitol, and citric acid com-saturation of the serum iron-binding capacity [10].
Iron dextran infusion has been reported to have in- pound in the same buttock. Similarly, a 40-year-old
woman received Jectofer for anemia of pregnancy, andduced systemic lupus erythematosis in a patient with a
history of polyarthritis but no serologic evidence of lupus four years later, she developed myxoid liposarcoma of
the right buttock. Two patients developed neoplasms[11]. A 36-year-old Chinese female developed iron-defi-
ciency anemia from menorrhagia and was treated with after intramuscular iron dextran as well. One was a 35-
year-old woman who was given iron dextran for anemiatotal dose iron therapy. Two days after receiving 2 g of
iron dextran, she developed a malar rash, polyarthritis, of pregnancy. She developed a rhabdomyosarcoma of
the right buttock 13 years later. In another case, a 51-periungual vasculitis, elevated erythrocyte sedimenta-
tion rate to 122 mm, positive antinuclear antibody year-old woman received intramuscular injections of
iron dextran in the buttock for iron-deficiency anemia.(ANA) at 1:320 dilution and anti-double-stranded DNA
antibody (anti-DS DNA) 25.3 mg/liter. The illness re- Several months later, a palpable thickening occurred at
the injection site. Biopsy revealed poorly differentiatedsolved rapidly after five days of prednisolone, and her
disease was at baseline eight months later with ANA chondrosarcoma [15]. Although there is no definitive
evidence that intramuscular iron therapy results in neo-titer at 1:80 and undetectable anti-DS DNA. Two years
later, the patient was rechallenged with 20 mg of intrave- plasm formation, we have used the intravenous route
for our own patients to avoid potential complicationsnous iron dextran and again developed polyarthritis, leu-
kopenia, lymphopenia, an ANA 1:160, and anti-DS and discomfort of intramuscular injection.
DNA 20.9 mg/liter.
The proposed mechanism(s) of the increased likeli- IRON OVERLOAD
hood of adverse reactions to iron dextran in patients
The improper administration of iron can result in ex-with collagen vascular disease includes hypersensitivity
cess iron stores. The oral recommended daily allowanceto dextran, direct toxic effects of iron on synovium by
of iron is 15 mg/day, with healthy adults absorbing 5%the generation of free radicals and peroxidation of lipids,
to 10% of dietary iron. This is the basis for the estimatedand/or reticuloendothelial system blockade resulting in
parenteral need for approximately 1 mg/day. This amounta secondary immune complex synovitis [10, 12, 13].
offsets obligate losses from desquamation of skin and
mucosa from gut and genitourinary tract. The body’s
IRON-INDUCED MUSCLE DISEASE ability to excrete parenterally administered iron is lim-
ited to these daily losses and to losses during phlebotomyFoulkes et al reported a case of rhabdomyolysis after
parenteral iron administration, a 59-year-old man with or hemodialysis.
Excess dietary or parenteral iron is sequestered by thechronic malabsorption, selective IgA deficiency, and se-
vere iron-deficient anemia. Additionally, the patient was reticuloendothelial system and can result in hepato-
splenic siderosis. Hepatosplenic siderosis is a secondaryselenium and vitamin E deficient. The patient was intol-
erant to oral iron therapy and received several intramus- cause of iron overload, whereas hereditary hemochro-
matosis (HH) represents a primary etiology. The geneticcular injections of iron dextran over a four-week period.
Eighteen days later, he developed severe generalized frequency of HH in the United States and Europe is
0.2% to 0.7% for homozygotes and 8% to 14% for het-myalgia, muscle weakness, and dark urine. Creatine ki-
nase was 20,400 IU/liter. Urinary myoglobin was strongly erozygotes [16]. Patients with homozygous or heterozy-
gous HH are at increased risk for developing iron over-positive, and muscle biopsy demonstrated regenerating
myocytes. Autoimmune markers remained negative, sug- load without iron supplementation, and baseline iron
status should be established prior to provision of paren-gesting against autoimmune polymyositis. The authors
propose that deficiencies of vitamin E and selenium in teral iron.
Fleming et al performed five biopsies and reviewed 17conjunction with parenteral iron resulted in free radical
oxidative injury to muscle membranes and rhabdomyo- autopsy liver specimens in 22 patients receiving chronic
hemodialysis for renal failure. Of these, 13 patients werelysis [14]. Therefore, patients receiving parenteral iron
therapy should be screened for other micronutrient and treated with parenteral iron dextran. Specimens were
assessed for hepatic iron content and histologic iron de-macronutrient deficiencies.
Although not proven, there may be an association position. Five patients had mild hepatic fibrosis with iron
present in hepatocytes. Two patients had high hepaticbetween intramuscular iron injection and the develop-
Burns and Pomposelli: Toxicity of parenteral iron dextran therapyS-122
iron concentrations in excess of 1000 mg per 100 mg mechanisms include decreased intestinal iron absorption
and cytokine-mediated sequestration of iron into tissuedry weight. Eight patients had elevated serum ferritin
concentrations some in conjunction with fibrosis [17]. stores, predominantly with the flux of iron into the reticu-
loendothelial system and the liver [21–23].In a histologic study of spleens obtained from 40 pa-
tients on maintenance hemodialysis treated with iron The relationship between infection and iron deficiency
is unclear and remains controversial [24]. McFarlane et aldextran, Murray et al demonstrated that 24 of the speci-
mens (60%) had massive splenic iron loading [18]. Pa- studied 40 children with kwashiorkor-type malnutrition
and low serum transferrin. Children were given nutri-tients routinely received 250 mg of parenteral iron dex-
tran per month until serum ferritins became elevated, tional support that included oral iron supplements. Many
of the children who received iron therapy died shortlyand then supplements were discontinued. The amount
of splenic deposition correlated with the total amount after supplements were begun, suggesting a temporal
relationship [25]. The provision of iron in the setting ofof iron dextran administered.
Ali et al studied the relationship between serum ferri- low serum transferrin may result in higher circulating
free iron that could have contributed to the developmenttin and iron deposition in the liver, spleen, and bone
overwhelming infection and death.marrow in 36 patients with chronic renal failure. Patients
Septicemia with Yersinia enterocolitica has been re-had received a mean of 5450 mg of elemental iron as
ported in healthy children who took overdoses of oraliron dextran. Twenty-three of 36 patients had advanced
iron [26]. Iron-deficient Somali nomads treated with oralhepatosplenic siderosis with three to four plus iron de-
iron demonstrated a greater than fivefold increase inposits, which correlated with elevations in serum ferri-
infectious complications compared with placebo, mosttins. However, in 10 of the iron-overloaded patients,
of which represented reactivation of underlying malaria,bone marrow specimens were iron depleted [19]. These
brucellosis, or tuberculosis [27].studies were limited in that patients did not receive eryth-
Seifert et al studied 39 patients with end-stage renalropoietin therapy. Erythropoietin facilitates rapid trans-
failure on maintenance hemodialysis that were treatedfer of iron sequestered in the liver and spleen to the
with desferrioxamine. Desferrioxamine is a chelatingbone marrow for developing red blood cells. The devel-
agent used to reduce iron and/or aluminum stores inopment of iron overload is facilitated by parenteral ad-
patients with overload. Twenty-three patients receivedministration of iron because the intestinal regulatory
desferrioxamine for aluminum-related bone disease andmechanisms are bypassed.
16 patients due to iron overload. A control group con-
sisted of 193 patients on maintenance dialysis who were
IRON AND INFECTION not treated with desferrioxamine. There was no differ-
Infection and injury initiate a systemic inflammatory ence in the incidence of sepsis in the control group com-
response (SIR), the goals of which are to limit injury, aid pared with patients with aluminum-related bone disease
tissue repair, and augment immunity. Classic responses treated with desferrioxamine. The incidence of sepsis in
include fever, hypotension, tachycardia, hyperglycemia, the iron-overloaded group treated with desferrioxamine
increased protein catabolism, and decreased iron-trans- was almost three times that of the control group (0.36
ferrin saturation while increasing serum levels of copper vs. 0.12 sepsis episodes per patient therapy year, P ,
and zinc. Elevated release of cytokines are the hallmark 0.001).
and include interleukin-1, tumor necrosis factor, and in- To study the infectious risk of iron overload, patients
on hemodialysis who had never received desferrioxa-terleukin-6 [20]. These occur in conjunction with ele-
vated levels of glucagon, cortisol, and epinephrine and mine were further subdivided. Patients were stratified
according to serum ferritin levels: group I (ferritin 10 toserve to mediate the metabolic cascade of the systemic
inflammatory response. 330 mg/liter, N 5 125), group II (ferritin 331 to 1000 mg/
liter, N 5 49), and group III (ferritin 1001 to 2000 mg/Several authors have demonstrated that in vitro sup-
plementation of iron can overcome natural immunity liter, N 5 10). Patients with moderate-to-severe iron
overload (groups II and III) had a significantly higher[21–23]. In general, doubling the saturation of the iron-
binding protein in animal models yields a marked in- incidence of sepsis compared with controls (group I; 0.18
vs. 0.58 infections per patient therapy year, P , 0.01)crease in the growth of various pathogens. Microorgan-
isms require iron for growth and must acquire iron from [28].
Tielemans and Lenclud studied a similar patient popu-their host. Microbes synthesize iron transport proteins
or siderophores that compete with transferrin for free lation on maintenance hemodialysis never exposed to
desferrioxamine [29]. The authors reviewed infectiousiron. Depressed serum iron levels, a physiological de-
fense mechanism, have been documented during sepsis risk according to cumulative exposure to hemodialysis
expressed in patient-years. In patients with normal serumand may be mediated by interleukin-1 [22]. Proposed
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